Compound profile · Recovery research

CJC-1295

A short-acting GHRH analog studied for pulsatile growth-hormone release.

Tissue research Janoshik verified
StatusResearch use only
BPC-157 - 10 mg
BPC-157 - 10 mg
Dhs. 349.00
Shop now
01

A cleaner pulse.

CJC-1295 without DAC - also called Modified GRF (1-29) - is a stabilized fragment of growth-hormone-releasing hormone. Without the DAC modification it is short-acting, producing a pulse of GH release that more closely mirrors the body's own rhythm.

01
GHRH mimicry
Binds pituitary GHRH receptors to stimulate endogenous GH output.
02
Short half-life
Roughly 30 min–2 h, favoring physiological pulsing over saturation.
03
Synergy partner
Studied with ghrelin-receptor agonists like Ipamorelin for amplified pulses.
Primary structure
Mod. GRF (1-29) · Tyr-Ala-Asp-Ala-Ile-Phe-…
Mod GRF (1-29) · ~3367 g/mol
Calculate your reconstitution dosage →
03

At a glance

29
Amino acids
30m - 2h
Min half-life (rat)
GHRH-R
CAS
04

The GHRH side of the synergy.

The growth-hormone axis has two upstream levers: GHRH (the 'go' signal) and ghrelin/GHS (the amplifier). CJC-1295 occupies the GHRH side.

Without DAC, it does not bind albumin for extended action, so it clears quickly. Research interest centres on preserving the pulsatile pattern of GH secretion rather than flooding the system - which is why it is rarely studied alone.

05

Not all claims are equal.

Tier 01
Strongest support
  • GHRH-receptor binding and GH stimulation (characterised)
  • Pulsatile GH release preserved vs continuous analogs
  • Synergy with GHS compounds documented
Tier 02
Moderate support
  • Downstream IGF-1 elevation in studies
  • Body-composition signals in limited research
  • Comparisons of DAC vs no-DAC kinetics
Tier 03
Emerging / unverified
  • Long-term human outcomes
  • Anti-ageing positioning
  • Optimal research dosing windows
06

How it works

01
GHRH receptor

Agonist at pituitary somatotroph GHRH receptors.

Characterized
02
Pulsatile release

Short action preserves natural GH pulse architecture.

Research
03
IGF-1 axis

GH elevation feeds downstream IGF-1 signaling.

Downstream
04
Synergy

Combines with GHS agonists for greater pulse amplitude.

Documented
07

How it moves through the system

AdministrationPeakHalf-lifeCleared
Peak 50% Cleared
~30 min
Onset to peak
30 min–2 h
Half-life
hours
Largely cleared
Curve shape is illustrative; figures reflect pharmacokinetics reported in research — rapid local metabolism, figures from animal IV/IM data.
08

Used in the lab, not the clinic

Reference figures describe how this compound is handled and dosed in research. These are not instructions for human use.

Format & handling
Research formatLyophilised
ReconstitutionBacteriostatic water
Cold-chainRecommended
In the literature
Doses in literatureµg/kg (animal)
Storage−20 °C lyophilised
Stability (reconstituted)~weeks, refrigerated
09

Reconstitution calculator

How much diluent to mix into the vial, and the concentration that results. The suggested volume reaches a clean working stock; the calculator does the arithmetic from figures you enter. These describe solution preparation for research handling — not instructions for use in humans or animals.

Suggested reconstitution Reconstitute the 10 mg vial with 2 mL bacteriostatic water → 5.0 mg/mL (5000 mcg/mL)
Concentration—
Volume / aliquot—
U-100 units—
Aliquots / vial—
Concentration = compound ÷ diluent. Volume per aliquot = target ÷ concentration. U-100 units are a volume readout (1 mL = 100 units). Figures are for research solution preparation only — not instructions for use in humans or animals.
010

Signs of a quality compound

Lyophilised cake or powder
A fine, fluffy white cake — not oily, clumped or discoloured.
Clear reconstitution
Dissolves to a clear, colourless solution with no visible particles or cloudiness.
Batch-specific COA
Independent HPLC purity and mass-spec identity for the exact lot — not a recycled generic PDF.
Intact seal & vacuum
Sealed flip-top vial under vacuum; correct fill; legible batch and storage marking.
Walk away if…
No COA, oily residue, off-colour, partial vacuum, or purity claims with no independent test behind them.
Suspiciously cheap
Pricing far below the market for a well-tested compound usually means skipped testing or underfilled vials.
Regulatory & status
A research staple, not a drug.

CJC-1295 is not approved for human use and is sold as a research compound. It is prohibited in competitive sport.

Status
Investigational research compound
Approval
Not FDA-approved
Anti-doping
Prohibited in sport
Pairing
Studied with Ipamorelin
Research handling
Important notices
  • For research purposes only
  • Not for human consumption
  • Not FDA approved
  • Consult a qualified professional
Important

For research use only. Not for human consumption. Apex Academy is an educational reference describing findings reported in published and preclinical literature. Nothing here is medical advice, a protocol, or a recommendation to administer any compound to humans or animals. Many compounds described are investigational and are not approved by the FDA or other regulators for the prevention, treatment, or cure of any condition. Their long-term safety and pharmacokinetics remain incompletely characterized. Dose ranges, where shown, describe quantities used in cited research models - not instructions for use. Consult a qualified, licensed professional before making any health decision.